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ABSTRACT
Introduction: The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an important emerging
respiratory pathogen. MERS-CoV resulted in multiple hospital outbreaks within and outside the Arabian
Peninsula. The disease has a high case fatality rate, with the need for a therapeutic option.
Areas covered: In this review, we provide an overview of the progress in the development of
therapeutic strategies for MERS. We searched PubMed, Embase, Cochrane, Scopus, and Google
Scholar, using the following terms: ‘MERS’, ‘MERS-CoV’, ‘Middle East respiratory syndrome’ in combina-
tion with ‘treatment’ or ‘therapy’.
Expert commentary: There are multiple agents tried in vitro and in vivo. None of these agents were
used in large clinical studies. Available clinical studies are limited to the use of the combination of
interferon and other agents. These clinical studies are based solely on case reports and case series.
There are no prospective or randomized trials. There is a need to have prospective and randomized
clinical trials for the therapy of MERS-CoV. However, this strategy might be hampered by the sporadic
cases outside the large hospital outbreaks.
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1. Introduction
The Middle East respiratory syndrome coronavirus (MERS-CoV)
emerged as an important virus in 2012 and since then has
caused multiple outbreaks in hospitals especially in the
Kingdom of Saudi Arabia and outside the Arabian Peninsula
[1–3]. Since the emergence of MERS-CoV, a total of 1800 cases
including 640 deaths were reported by the World Health
Organization (WHO) [4]. Due to the increased morbidity and
mortality of MERS-CoV infection, the attention was directed
toward the development of prevention strategies and the
establishment of therapeutic modalities. An earlier review
was based on the severe acute respiratory syndrome (SARS)
experience and had suggested few possible options for the
treatment of MERS-CoV infection [5]. In this review, we provide
an overview of the progress in the development of therapeu-
tic strategies for MERS.
2. Search strategy and classification of reviewed
articles
We searched PubMed, Embase, Cochrane, Scopus, and Google
Scholar using the following terms: ‘MERS,’ ‘MERS-CoV,’ ‘Middle
East respiratory syndrome’ in combination with ‘treatment’ or
‘therapy.’Wealso reviewed the references of each article to further
include other studies or reports not identified by the search. We
classified the studies into the following categories: in vivo and in
vitro studies, animal studies, and human case reports or case series.
For clinical studies, we graded the level of the evidence based on
the ‘Oxford Centre for Evidence-based Medicine’ [6].
3. In vivo and in vitro studies
In vitro studies showed variable activity of various agents against
MERS-CoV (Table 1). These agents include: interferon, ribavirin,
HIV protease inhibitors (nelfinavir, ritonavir, and lopinavir).
Interferon is antiviral type I IFN system, a major part of the
innate immune response [7,8]. In vitro studies showed that
IFN-β has an IC50 of 1.37 U/mL and that IFN-β has anti-
MERS-CoV activity of 16-, 41-, 83-, and 117-fold higher than
IFN-α2b, IFN-γ, IFN-universal type 1 and IFN-α2a, respectively
[9]. In vitro studies showed that IFN-β has a lower IC50 for
MERS-CoV compared to IFN-a2b [9].
Ribavirin is a nucleoside analog that is activated by host kinases
to a nucleotide [7,10,11]. It was shown that in vitro doses of
ribavirin required to inhibit MERS-CoV replications are too high
to be achieved in vivo [7,10]. Nelfinavir and lopinavir inhibit MERS-
CoV in vitro [7,12]. Themean 50% effective concentration (EC50) of
lopinavir using Vero E6 and Huh7 cells was 8.0 μM [13].
Camostat and the heptad repeat 2 peptide (HR2P) are two
MERS-CoV fusion inhibitors that were tested in vitro [14,15].
The fusion inhibitor, camostat, inhibited viral entry into human
bronchial submucosal gland-derived Calu-3 cells but not the
immature lung tissue [14]. The second fusion inhibitor, HR2P,
inhibits MERS-CoV replication and the spike protein-mediated
cell-cell fusion [15].
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Cyclosporin affects the function of many cyclophilins that
act as chaperones and facilitate protein folding [16,17]. In vitro,
cyclosporine inhibited MERS-CoV replication [16,17].
Nitazoxanide, a broad-spectrum antiviral agent, and teicopla-
nin, an inhibitor of cathepsin L in the late endosome/lysosome
and blocker of the entry of MERS-CoV, also showed inhibitory
effect of MERS-CoV in vitro [18,19].
4. Animal model and the use of anti-MERS-CoV
agents
There are few studies evaluating various agents as therapy for
MERS-CoV in animal models (Table 2) [12,21–24]. In the rhesus
macaques model, interferon-α2b-ribavirin combination decreased
viral replication within 8 h of MERS-CoV infection [25]. In a primate
model, the mortality rate at 36 h post-inoculation was reduced
from 67% in untreated to 0–33% in animals treated with a combi-
nation of interferon-β1b and either lopinavir or ritonavir [12].
Intranasal use of an HR2P analog with improved pharmaceutical
property, HR2P-M2,wasprotective inmicemodel [21]. In an animal
model using MERS-CoV infected mice, the use of high titer MERS
immune camel serum was effective in reducing lung injury and
acceleration of virus clearance [22]. Mycophenolate has a direct
and indirect antiviral activity by modulation of IFN response [20].
The use of mycophenolate in the common marmoset animal
model resulted in higher mortality than untreated animals [12]. A
monoclonal antibody designated as m336 is an antibody derived
from a large phage-displayed antibody library from B cells of
healthy donors [26]. The use of this m336 in mice showed promis-
ing results as a therapeutic and a prophylactic agent [23].
Currently, there is no animal model that completely reflects
the course of MERS-CoV disease in humans and thus the data
obtained from these animal models are to be interpreted cau-
tiously. And animal models utilize therapy shortly after infection.
5. Clinical use of combination therapy of ribavirin-
interferon in MERS-CoV patients
Based on analysis of SARS data, interferon-ribavirin combination
was suggested as a possible therapeutic option for the
treatment of MERS-CoV infections [5]. Limited data are available
regarding the clinical efficacy of antiviral agents [27–36]
(Table 3). The first use of the combination of ribavirin-interferon
therapy was in five patients with MERS infection [27]. The
therapy was started late in the course of the disease with a
median time from admission to therapy of 19 days [27]. Of the
included 5 patients, none responded to therapy [27].
In a subsequent retrospective cohort study, 20 MERS
patients received ribavirin-interferon compared to 24 patients
who did not [28]. The 14-day survival rate was better in those
who received the combination therapy (70% vs. 29%,
p = 0.004); however, the 28-day survival rate was not statistically
different (30% vs. 17%) (Table 1) [28]. In another case series, 11
MERS patients had ribavirin and peg-interferon α-2a [29].
Ribavirin-IFN-α2a was compared to ribavirin-IFN-β1a in a
study of 13 and 11 patients, respectively [30]. The mortality
rate was not statistically different between the two groups
(85% vs. 64%) [30]. In a large cohort study of 51 patients,
various combinations of interferon and ribavirin were used
with different outcomes (Table 3) [31]. In a case series of 6
patients, 3 patients received ribavirin and interferon-alfa 2b
within 1–2 days of admission and they survived compared to
the other 3 patients who died as they received the therapy
12–19 days after admission [36]. Another study evaluated the
use of interferon beta, interferon alpha, or ribavirin and
showed survival rates of 18/23 (78.3%), 6/8 (75%), and 13/19
(68.4%), respectively (Table 3) [31]. The combination therapy
was also used in other case reports (Table 3) [33,34].
Table 1. A summary of anti-MERS-CoV agents used in vitro and the mechanism
of action.
Molecule Mechanism of action Reference
Interferon (IFN) Antiviral type I IFN system, a major
part of the innate immune
response
[7–9]
Ribavirin A nucleoside analog that is activated
by host kinases to a nucleotide
[7,10,11]
Nelfinavir Protease inhibitor [7,12,13]
Lopinavir Protease inhibitor [7,12,13]
Camostat Fusion inhibitor [14]
Heptad repeat 2
peptide (HR2P)
Fusion inhibitor [15]
Cyclosporine Affects the function of many
cyclophilins that act as chaperones
and facilitate protein folding
[16,17]
Nitazoxanide Broad-spectrum antiviral agent [18,19]
Teicoplanin Inhibits cathepsin L in the late
endosome/lysosome and block the
entry of MERS-CoV
[18,19]
Mycophenolate Direct and indirect antiviral activity by
modulation of IFN response
[20]
Table 2. A summary of animal model of therapeutic agents against MERS-CoV
infection.
Number
Animal
model Treatment Outcome Reference
1 Primate Interferon-β1b
and either
lopinavir or
ritonavir
Mortality rate at 36 h
post-inoculation was
reduced from 67% in
untreated to 0–33%
in animals treated
with a combination
of Interferon-β1b
and either lopinavir
or ritonavir
[12]
2 Mice HR2P analog >1000-fold reduction of
viral titers in lung
[21]
3 Mice High-titer MERS
immune
camel serum
Increase the kinetics of
MERS-CoV clearance
and decrease
severity of
pathological changes
[22]
4 Primate Mycophenolate Mortality rate was 67%
(untreated and MMF
treated) at 36 h post
inoculation vs.
0–33% (lopinavir/
ritonavir-treated and
interferon-β1b-
treated)
[12]
5 Transgenic
mice
Germline-like
neutralizing
human
monoclonal
antibody
Treated mice prior to or
post lethal MERS-
CoV challenge were
fully protected
[23]
6 Mouse
model
Humanized
monoclonal
antibody,
hms-1,
against RBD
Single-dose completely
protected transgenic
mice from lethal
MERS-CoV
[24]
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The role of the combination of ribavirin and IFN was also
tried as a treatment and a prophylaxis [34]. The current studies
of the use of ribavirin and IFN combination therapy for MERS-
CoV infection rely on small number of patients but there is a
trend for improvement. Thus, it was suggested that the com-
bination of type 1 interferon and ribavirin could be used [37].
Due to the inhomogeneous nature of available studies and the
limited data that are available, a precise recommendation on
therapy of MERS could not be established.
6. Other combinations (lopinavir/ritonavir, ribavirin,
and interferon)
The combination of lopinavir/ritonavir, ribavirin and interferon-
alpha was used in one case [32]. One patient received pegylated
interferon, ribavirin, and lopinavir/ritonavir from day 13 of illness
and the patient had continued MERS-CoV in the respiratory tract
secretions until the fourth week of illness [33]. However, viremia
was detected for only 2 days after initiation of triple therapy [33]. In
a case series, eight patients received mycophenolate mofetil and
all survived [31].
7. Neutralizing antibodies
In the SARS epidemic, passive immunotherapy with neutralizing
antibodies was considered as a therapeutic approach. There are
multiple antibodies against MERS-CoV [38–48] (Table 4). In the
MERS-CoV infection, the production of large quantities of MERS-
CoV neutralizing human polyclonal antibodies was possible
using gamma-irradiated whole-killed virion vaccine or a spike
protein nanoparticle vaccine in a bovine model [49]. Utilizing
one dose of these antibodies prevented infection in mice [49].
These antibodies were effective when given 12 h before or 24
and 48 h after MERS-CoV infection [49].
Corti et al. isolated a potent MERS-CoV-neutralizing antibody
(LCA60) from memory B cells of an infected individual. The LCA60
antibodies bind to a site on the spike protein and neutralizeMERS-
CoV infection [48]. These LCA60 antibodies were used successfully
in mice model [48]. Similarly, utilizing a humanized mouse model
of MERS-CoV infection, antibodies against the spike protein were
efficacious as prophylaxis [39]. Antibodies obtained from the sera
of MERS immune camels were supportive of the clearance of the
virus, and reduction of the severity of the disease in MERS-CoV-
infected mice [22]. However, the purification and safety of these
antibodies in humans has not been established yet.
The cellular dipeptidyl peptidase IV (DDP IV; known as
CD26 or adenosine deaminase (ADA)-complexing protein-2)
Table 3. Clinical experience with antiviral therapy for MERS-CoV infection.
Number Study type Treatment
Time to initiation of
therapy
Treatment group, n/N
(% survival) Control group Level of evidence Reference
1 Case series Ribavirin and
interferon-alfa 2b
19 days post-
admission
0/5 (0) None 4 [27]
2 Retrospective
cohort study
Ribavirin and
interferon-alfa 2a
3 days of onset 14/20 (70 at 14 days);
6/20 (30 at 28 days)
24; survival at 14 days
29% and 17% at
28 days
4 [28]
3 Case series Ribavirin and
interferon-alfa 2a
6 days of onset 11/11 (100) None 4 [29]
4 Case series Ribavirin and
interferon-alfa 2a
1 day following
diagnosis
11/13 (85) None 4 [30]
5 Case series Ribavirin and
interferon-b1a
1 day following
diagnosis
7/11 (64) None 4 [30]
6 Case series Interferon beta Not indicated 18/23 (78.3) None 4 [31]
7 Case series Interferon alpha Not indicated 6/8 (75) None 4 [31]
8 Case series Ribavirin Not indicated 13/19 (68.4) None 4 [31]
9 Case series Mycophenolate
mofetil
Not indicated 8/8 (100) None 4 [31]
10 Case report Lopinavir/ritonavir,
ribavirin, and
interferon-α
Not indicated None 4 4 [32]
11 Case report Pegylated interferon,
ribavirin and
lopinavir/ritonavir
From Day 13 of illness ? None 4 [33]
12 Case report Ribavirin and
interferon-alfa 2a
Day 1 of admission Survived None 4 [34]
13 Case report Ribavirin and
interferon-alfa 2a
Day 12 from onset Died None 4 [35]
14 Case series Ribavirin and
interferon-alfa 2b
1–2 days in survivals
and 12–19 days in
those who died
3/6 (50) None 4 [36]
Table 4. A summary of generated anti-MERS-CoV antibodies.
Number Antibody Reference
1 Anti-CD26 monoclonal antibody [38]
2 Anti–MERS-CoV spike protein antibodies [39]
3 Recombinant receptor-binding domain of S spike [40]
4 Receptor-binding domain in S spike protein [41]
5 Receptor-binding domain in S spike protein [42]
6 Receptor-binding domain in S spike protein [43]
7 Receptor-binding domain in S spike protein [44]
8 Receptor-binding domain in S spike protein [45]
9 S spike protein [46]
10 Human neutralizing antibodies [44]
11 Human monoclonal antibodies against CD26/DPP4-
binding domain
[45]
12 Human RBD-specific neutralizing monoclonal antibodies [43]
13 A human anti-MERS monoclonal antibody 3B11-N [47]
14 S spike protein [48]
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is an important receptor that mediates MERS-CoV infection
through the viral spike (S) protein [46,50]. The MERS-CoV
receptor binding domain (RBD), present on the surface spike
protein (S), binds to the host cells receptor DPP IV [46,50,51].
In humans, DPP IV is present mainly on the lower respiratory
tract area such as the bronchial epithelial and alveolar cells
[52,53]. Although DDP IV is important for the viral entry into
host cells, the use of DPP IV inhibitors, sitagliptin, vildagliptin,
and saxagliptin, does not block the infection of MERS-CoV [50].
In vitro use of monoclonal antibodies (MERS-4) exhibited IC50
of 0.056 µg/mL [43]. Other possible human mAb (m336, m337,
and m338) neutralize pseudovirus and live virus [45]. In rhesus
model of MERS-CoV infection, a human monoclonal antibody,
3B11-N, against MERS-CoV was effective in reducing the
pathology of MERS-CoV [47]. The use of polyclonal antibody
(pAb) against CD26 inhibits MERS-CoV infection in vitro [50].
Humanized anti-CD26 monoclonal antibodies (MAb) such as
MAb YS110 and 2F9 significantly inhibit MERS-COV infection in
vitro [38]. Polyclonal antibodies against the MERS-COV S1
domain neutralize the virus infection [46]. Many other MERS-
CoV antibodies are being developed and tested [38].
8. Convalescent plasma
In the SARS epidemic, convalescent plasma was thought to
improve the outcome of SARS patients [5]. Previous studies
suggest that convalescent plasma may be used for patients
with SARS and severe influenza and may result in decreased
viral load and a lower mortality rate [54–57]. However, most of
the studies were of low or very low quality, lacked control
groups, and had risk of bias [58]. Two patients with MERS-CoV
infection received intravenous immunoglobulin in an attempt
to treat the infection, one patient was in Saudi Arabia [59] and
the other was in the USA [60]. A protocol for the use of
convalescent plasma as a therapeutic option for MERS was
suggested [61]. Plasma donors were identified as those with
anti-MERS-CoV indirect immunofluorescence assay (IFA) anti-
bodies (titer of ≥1:160) with no evidence of active MERS-CoV
infection [61]. In nine confirmed survivors of MERS-CoV infec-
tion, 55%, 33%, and 22% of them had positive MERS antibo-
dies by IFA at 3, 10, and 18 months, respectively [62]. The two
patients who had long lasting antibodies had severe disease;
however, the titer of the IFA antibodies was not measured in
the study [62]. In a larger study, MERS-CoV neutralizing anti-
bodies were produced at low levels and were short-lived [63].
Further studies of the kinetics of the MERS-CoV antibodies
showed that all surviving patients and 50% of fatal cases
produced IgG and neutralizing antibodies [64]. The presence
of antibodies did not lead to the elimination of virus from the
lower respiratory tract [64]. In a study of 12 patients from
South Korea, nine patients had PRNT50 titers >1:320 by day
21 and two had titers >1:320 by day 28 [65]. In a study of 443
samples, 12 (2.7%) had reactive ELISA results, and 9 of those
had reactive indirect fluorescent antibody and microneutrali-
zation assay titers [66]. Thus, the use of convalescent plasma
for the treatment of MERS-CoV in a clinical trial may be
challenging due to a small pool of potential donors with
sufficient antibody titers [66].
9. Glucocorticoid
Based on SARS experience, some authors suggested that ster-
oid therapy might be beneficial for severe MERS-COV infection
[67]. Corticosteroid use for patients with SARS showed that
early use of corticosteroids significantly increased viral load,
and 20.7-fold increase in risk of ICU admission and mortality
[68]. In another study of 16 non-ICU patients, the median time
for SARS-CoV to become undetectable in plasma was 12 days
compared to 8 days in patients who did and did not receive
early corticosteroid therapy [69].
Corticosteroids were used as adjunct therapy for many
patients with MERS-CoV [27,70]. In a study of 13 patients
with MERS-CoV infection, one patient received steroid and
intravenous immunoglobulin for thrombocytopenia [59].
Initial study of five patients, three patients received a combi-
nation of interferon and ribavirin in addition to adjunct steroid
on day 0–21 and all died during hospitalization [27]. However,
steroids were not evaluated systematically as therapy for MERS
patients.
10. Other therapeutic drugs
The host protease, furin, is an important factor to break down
the S1-S2 region of the MERS-CoV [71]. In vivo studies showed
activity of multiple agents against MERS-CoV and include:
chloroquine, chlorpromazine, cyclosporine, and mycophenolic
acid [7,72]. In addition, the US FDA approved repurposed
agents with broad antiviral activity including in vitro activity
against MERS-CoV [73]. These agents include the polymerase
inhibitor BCX4430 and the helicase inhibitor SSYA10-001,
spike binding (immunoadhesin (DPP4-Fc)) [73]. There are
many other agents currently in preclinical investigation such
as: fluspirilene, thiothixene, fluphenazine hydrochloride, pro-
methazine hydrochloride, astemizole and chlorphenoxamine
hydrochloride [72].
11. Expert commentary
The emergence and continued cases of MERS-CoV infection
require the availability of MERS therapy. There is an urgent
need for the development of standardized animal models
and the establishment of standardized clinical therapeutic
protocols. The current clinical studies are limited to case
reports and case series with no control arm. The quality of
evidence these studies offer is too low to make a conclusion.
It is difficult to draw conclusion in the face of these limited
studies. The most used combination of therapy was inter-
feron and ribavirin as developed initially in 2013. The devel-
opment of novel therapeutic agents or the repurposing old
therapeutic agents against MERS-CoV are needed as alter-
native pathways for testing and clinical trials. It was thought
that convalescent sera may provide an exciting alternative
as a therapeutic agent; the present data does not support
the wide adaptation of this therapy. The current MERS ther-
apy relies on supportive care and providing circulatory and
ventilation support.
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12. Five-year view
It is expected that the development and the use of repur-
posed drugs would allow the development of therapeutic
agents for MERS-CoV. The best location to provide a rando-
mized controlled trail was thought to be the intensive care
units for the use of convalescent sera; the presence of milder
disease may necessitate the development of therapeutic pro-
tocols for patients with severe and those with milder disease.
Monoclonal and polyclonal antibodies may offer further ther-
apeutic options for the disease in humans. Since the prospect
for a randomized clinical trial is low due to the sporadic nature
of the disease outside hospital outbreaks, it is prudent to have
well-conducted prospective clinical studies. The proteins
involved in MERS-CoV entry and replication are attractive
targets for the development of antiviral therapeutics. Clinical
studies utilizing anti-MERS-CoV antibodies as therapeutic
options would add to the prospect to develop therapeutic
agents for this syndrome. Although many drugs appear to
be effective in vitro, a consideration of their availability, phar-
macokinetic/pharmacodynamic properties, and side effects
should be taken into consideration. Of medications with an
attractive use, lopinavir, interferon, and mycophenolate are
among these agents. Accelerated and preferably randomized
controlled trails should be conducted. Neutralizing antibodies
are also promising and the use of these agents in humans.
Targeting the DDP4 receptor may be of particular importance;
however, it is important to keep in mind that the development
of any mutation in the binding sites may limit the use of these
agents [74]. Few monoclonal antibodies showed protective
efficacy as a prophylaxis in animal models [39,48]. The devel-
opment and testing of monoclonal antibodies are associated
with high costs and lack of an undefined population for their
use [75]. These monoclonal bodies had not been used in
phase 1 clinical trials and that further development of these
agents require time and cost.
Key issues
● MERS-CoV emerged in 2012 and has caused multiple hos-
pital outbreaks.
● Currently, there are no licensed therapeutic agents for
MERS-CoV infection.
● Multiple monoclonal and polyclonal antibodies were devel-
oped and may offer therapeutic options.
● Repurposing old drugs against MERS-CoV is an interesting
strategy that deserves further development and use in
clinical settings.
● Current clinical data are limited to case reports and case
series in the use of combination antiviral medications such
as ribavirin and interferon.
● The combination of ribavirin and interferon may offer a
survival advantage at 14 days but not at 28 days.
● Animal models are promising in further delineating the
disease and the therapeutic options.
● Further studies should include in vitro mechanism studies,
enhancing animal models of MERS-CoV infection, clinical
trials, and evaluation of combination therapy.
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